Since the ADAURA trial showed that adjuvant osimertinib after resection significantly improved PFS [27], the combination of local therapy and targeted therapy could be efficacious for stage III NSCLC harboring mutations in EGFR. Here, EGFR is linked to non-small cell lung carcinoma.